表紙
市場調查報告書

多發性硬化症 (MS) - 醫藥品的全球市場的預測與分析

Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 920909
出版日期 內容資訊 英文 356 Pages
訂單完成後即時交付
價格
Back to Top
多發性硬化症 (MS) - 醫藥品的全球市場的預測與分析 Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2028
出版日期: 2019年12月31日內容資訊: 英文 356 Pages
簡介

多發性硬化症 (MS) 治療藥市場,由於可利用的治療選擇的劇增,與提供多樣的作用機制 (MOA) 的幾個有前途的後期開發中產品,而進入了刺激的階段。多發性硬化症 (MS) 治療藥市場銷售額,由於向患者提供許多選項,促進新競爭的11項新開發平台劑的推出,預計從2018年的198億美元,到2028年擴大到329億美元,年複合成長率 (CAGR) 成長5.2%。

本報告提供多發性硬化症 (MS)的治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,促進因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
  • 分類
  • 症狀
  • 預後
  • QOL

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 世界、歷史性的趨勢
  • 預測手法
  • 流行病學預測
  • 討論

第6章 疾病的管理

第7章 競爭評估

第8章 未滿足需求和機會的評估

第9章 開發平台評估

第10章 現在、未來的企業

第11章 市場預測

第12章 附錄

目錄
Product Code: GDHC181PIDR

Multiple Sclerosis (MS) therapeutics market has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering diverse mechanisms of action (MOA). The latest research report "Multiple Sclerosis: Global Drug Forecast and Market Analysis to 2028" expects the Multiple Sclerosis (MS) market to grow in sales from $19.8bn in 2018 to $32.9bn in 2028 with a compound annual growth rate (CAGR) of 5.2%, due to the launch of 11 new pipeline agents providing more options for patients and stimulating further competition.

Multiple Sclerosis (MS) is a primary autoimmune disease with a mechanism involving recurrent inflammatory attacks on the central nervous system (CNS) due to a dysfunctional immune system, leading to neurological disability. Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS, and is characterized by lymphocyte and macrophage infiltrates, as well as glial cell activation. Multiple Sclerosis (MS) patients are generally grouped into four major categories on the basis of the disease course. These categories are Relapse-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), and Progressive Relapsing Multiple Sclerosis (PRMS).

The Multiple Sclerosis (MS) pipeline is strong and diverse with a total of 49 products in all stages and phases of clinical development, of which 24 are early-stage and 25 are in the late-stage pipeline. Progressive Multiple Sclerosis (MS) is a significant focus for product development, with seven of the late-stage products targeting this patient group as an initial indication. There is currently a distinct lack of Disease Modifying Therapies (DMT) options for patients with progressive Multiple Sclerosis (MS) subtypes, and these populations remain significantly underserved.

The 11 new pipeline agents have a broad range of MOA, including anti-CD20 antibodies, three second generation S1P receptor modulators, an anti-LINGO-1 antibody, a tyrosine kinase inhibitor, a Repulsive Guidance Molecule A (RGMA) Inhibitor and antioxidants. Further, 14 late-stage drug products will launch in the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) during, or shortly after, the forecast period from 2018 to 2028.

While physicians might be persuaded that there may be some advantages of the newer generation, the pipeline developers may find it difficult to persuade payers, or insurance companies to use their drug over fingolimod generics, especially in the US, where branded drug prices are high.

The current Multiple Sclerosis (MS) market is highly competitive, with 14 available treatment options, most of which are immunomodulatory agents. The majority of approved treatments address the inflammatory and systemic origins of the disease, but few possess neuroprotective effects and, as such, have an insufficient impact on the underlying neurologic deterioration caused by Multiple Sclerosis (MS). Remyelination strategies could prove revolutionary for Multiple Sclerosis (MS), as they address a key pathophysiological aspect of the disease that is thought to contribute to the accrual of permanent disability.

The Multiple Sclerosis (MS) market is heading towards earlier and more aggressive therapies, with studies in the US questioning whether people with Multiple Sclerosis (MS) who are recently diagnosed should already go on with one of the monoclonal antibody therapies.

Scope

  • Overview of Multiple Sclerosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized Multiple Sclerosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, SPMS and PPMS) forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Multiple Sclerosis therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Multiple Sclerosis therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global Multiple Sclerosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Multiple Sclerosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Multiple Sclerosis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Executive Summary

  • 2.1 Moderate Growth Expected in the MS Market from 2018 to 2028
  • 2.2 R&D and Corporate Strategies Within the MS Market
  • 2.3 Current Treatments Leave a High Level of Unmet Need in the MS Market
  • 2.4 Opportunities Remain for Products that Fulfill Significant Unmet Needs in the MS Market
  • 2.5 Late-Stage Pipeline Drugs Entering the MS Market Will Be a Key Driver of Growth
  • 2.6 What Do the Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification
    • 4.2.1 Relapsing-Remitting MS
    • 4.2.2 Secondary Progressive MS
    • 4.2.3 Primary Progressive MS
    • 4.2.4 Progressive Relapsing MS
  • 4.3 Symptoms
  • 4.4 Prognosis
  • 4.5 Quality of Life

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for MS (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of MS
    • 5.5.2 Age-Specific Diagnosed Incident Cases of MS
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of MS
    • 5.5.4 Diagnosed Prevalent Cases of MS
    • 5.5.5 Age-Specific Diagnosed Prevalent Cases of MS
    • 5.5.6 Sex-Specific Diagnosed Prevalent Cases of MS
    • 5.5.7 Diagnosed Prevalent Cases of MS by Type
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

7 Competitive Assessment

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: Multiple Sclerosis: Key Metrics in the Seven Major Pharmaceutical Markets
  • Table 2: Common Presenting Symptoms of MS
  • Table 3: Factors That Can Affect Prognosis in MS
  • Table 4: Risk Factors and Comorbid Conditions Associated with MS
  • Table 5: Revised 2017 McDonald Criteria for the Diagnosis of MS
  • Table 6: Treatment Guidelines for MS
  • Table 7: Top Three Disease-Modifying Therapies Prescribed for MS, by Market, 2018
  • Table 8: Pharmacotherapy for Common MS Symptoms
  • Table 9: US - MS Diagnosis Metrics
  • Table 10: US - MS Treatment Metrics
  • Table 11: France - MS Diagnosis Metrics
  • Table 12: France - MS Treatment Metrics
  • Table 13: Germany - MS Diagnosis Metrics
  • Table 14: Germany - MS Treatment Metrics
  • Table 15: Italy - MS Diagnosis Metrics
  • Table 16: Italy - MS Treatment Metrics
  • Table 17: Spain - MS Diagnosis Metrics
  • Table 18: Spain - MS Treatment Metrics
  • Table 19: UK - MS Diagnosis Metrics
  • Table 20: UK - MS Treatment Metrics
  • Table 21: Japan - MS Diagnosis Metrics
  • Table 22: Japan - MS Treatment Metrics
  • Table 23: Leading Disease-Modifying Drugs for the Treatment of MS, 2019
  • Table 24: Product Profile - Betaseron
  • Table 25: Efficacy Results for Betaseron in a Phase III (IFNBMS) Trial
  • Table 26: Betaseron SWOT Analysis, 2019
  • Table 27: Product Profile - Avonex
  • Table 28: Efficacy Results for Avonex in a Phase III Trial
  • Table 29: Avonex SWOT Analysis, 2019
  • Table 30: Product Profile - Rebif
  • Table 31: Rebif SWOT Analysis, 2019
  • Table 32: Product Profile - Plegridy
  • Table 33: Clinical and MRI Endpoints at Year 1 from a Phase III Trial of Plegridy in MS
  • Table 34: Clinical and MRI Endpoints at Year 2 from a Phase III Trial of Plegridy in MS
  • Table 35: AEs During Year 1 of a Phase III Trial of Plegridy in MS
  • Table 36: Plegridy SWOT Analysis, 2019
  • Table 37: Product Profile - Copaxone
  • Table 38: Copaxone SWOT Analysis, 2019
  • Table 39: Product Profile - Tysabri
  • Table 40: Efficacy Results for Tysabri in a Phase III (DECIDE) Trial
  • Table 41: Tysabri SWOT Analysis, 2019
  • Table 42: Product Profile - Lemtrada
  • Table 43: Efficacy Results for Lemtrada in a CARE II Extension Trial
  • Table 44: Lemtrada SWOT Analysis, 2019
  • Table 45: Product Profile - Ocrevus
  • Table 46: Efficacy Results for Ocrevus in a Phase III (OPERA I and OPERA II) MS Trial
  • Table 47: Efficacy Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials
  • Table 48: Efficacy Results for Ocrevus in Phase III (OPERA OLE) MS Trials
  • Table 49: Efficacy Results for Ocrevus in Phase III (ORATORIO OLE) MS Trials
  • Table 50: Safety Results for Ocrevus in Phase III (OPERA I and OPERA II) MS Trials
  • Table 51: Safety Results for Ocrevus in Phase III (ORATARIO) MS Trials
  • Table 52: Ocrevus SWOT Analysis, 2019
  • Table 53: Product Profile - Gilenya
  • Table 54: Gilenya SWOT Analysis, 2019
  • Table 55: Product Profile - Aubagio
  • Table 56: Aubagio SWOT Analysis, 2019
  • Table 57: Product Profile - Tecfidera
  • Table 58: Tecfidera SWOT Analysis, 2019
  • Table 59: Product Profile - Mavenclad
  • Table 60: Efficacy Results for Mavenclad in a Phase III (CLARITY and CLARITY EXTENSION) MS Trial

List of Figures

  • Figure 1: Sales for MS by Region, 2018-2028
  • Figure 2: Company Portfolio Gap Analysis in MS, 2018-2028
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2018-2028
  • Figure 4: Accrual of Disability in the Four Subtypes of MS
  • Figure 5: 7MM, Diagnosed Incidence of MS (Cases per 100,000 Population), Men and Women, All Ages, 2018
  • Figure 6: 7MM, Diagnosed Prevalence of MS (%), Men and Women, All Ages, 2018
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of MS
  • Figure 8: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS
  • Figure 9: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MS by Type
  • Figure 10: 7MM, Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
  • Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, N, Both Sexes, All Ages, 2018
  • Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, N, All Ages, 2018
  • Figure 13: 7MM, Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
  • Figure 14: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, N, Both Sexes, All Ages, 2018
  • Figure 15: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, N, All Ages, 2018
  • Figure 16: 7MM, Diagnosed Prevalent Cases of MS by Type, N, Both Sexes, All Ages, 2018
  • Figure 17: EDSS
  • Figure 18: Algorithm for the Treatment of MS with DMTs
  • Figure 19: Overview of the Unmet Needs in MS
  • Figure 20: Overview of the Development Pipeline in MS
  • Figure 21: MS Therapeutics - Clinical Trials by Country, 2019
  • Figure 22: MS - Phase II-III Pipeline, 2019
  • Figure 23: Competitive Assessment of Late-Stage Pipeline Agents in MS, 2018-2028
  • Figure 24: Company Portfolio Gap Analysis in MS, 2018-2028
  • Figure 25: Global Sales for MS by Region, 2018-2028
  • Figure 26: Global Sales for MS by Therapy Type, 2018-2028
  • Figure 27: Sales for MS in the US by Therapy Type, 2018-2028
  • Figure 28: Sales for MS in the 5EU by Therapy Type, 2018-2028
  • Figure 29: Sales for MS in Japan by Therapy Type, 2018-2028
Back to Top